$77,076,622

Department of Health and Human Services·Office of Assistant Secretary for Preparedness and Response

to CHIMERIX, INC.

biotechexpiredONGOING · MOD OF 2011 CONTRACT

WORK BEGAN2011-02-16·LATEST ACTION2026-05-18·SOURCEUSASPENDING·SOURCE IDCONT_AWD_HHSO100201100013C_7505_-NONE-_-NONE-

Award description

CHIMERIX INC BASE YEAR FUNDING CAN 1992002

Verbatim from USAspending.gov. Capitalization, abbreviations, and codes are unchanged.

The Buildout's read

What the model surfaced from this award

Confidence: high

In plain English

Continuation funding for CHIMERIX's antiviral drug development program under the HHS Office of Preparedness and Response, initiated in 2011.

Sub-sectors

antiviral-drug-developmentpandemic-preparednessaspr-medical-countermeasures

Why this matters

Supports U.S. biodefense and pandemic preparedness by advancing broad-spectrum antivirals for emerging infectious disease threats.

Supply-chain signal

Sustains domestic pharmaceutical R&D capacity for medical countermeasures; signals ongoing government investment in antiviral manufacturing readiness.

U.S.–China competition angle

Reflects U.S. commitment to domestic biotech resilience and reducing reliance on foreign pharmaceutical supply chains for critical antivirals.

Generated by award_classification v2.1.0 via claude-haiku-4-5-20251001 on 2026-06-01. Cost: $0.003056.

Period of performance

Start

2011-02-16

End

2021-09-01

Status

expired1768 days ago

Recipient

CHIMERIX, INC.

UEI KLDQF5TYQM45

View full profile →

Sources

USAspending.gov — all awards for this UEI →
SAM.gov entity registration →
Award record ingested from usaspending. Source identifier CONT_AWD_HHSO100201100013C_7505_-NONE-_-NONE-.

The Buildout does not edit federal records. Any inaccuracy reflects the upstream source; it will update here when corrected there.